Skip to main navigation Investors EMAIL ALERTS You may automatically receive Amarin Corporation plc financial information by email. Please enter your preferences for email notifications below Required fields denoted by an asterisk (). Alert type Quote By Email All SEC Filings Annuals Current Earnings & News Beneficial Ownership Securities Filings Press Releases Weekly Summary Email Unsubscribe from Investor Relations email alerts. Our email alerts provide automated opt-out methods as well as complete contact information. Shareholder Tools PRINTED MATERIALS EMAIL ALERTS RSS SEARCH © 2021 Amarin Corporation All rights reserved. Disclaimer Privacy Policy Contact Us Amarin is headquartered in Dublin, Ireland. In the U.S., the company's office is in Bridgewater, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN"). AMARIN, VASCEPA, VAZKEPA and REDUCE-IT are trademarks of Amarin Pharmaceuticals Ireland Limited. VAZKEPA is a registered trademark in Europe and other countries and regions and is pending registration in the United States.

Skip to main navigation Investors PUBLICATIONS The following publications, posters and citations are provided for investors and should not be construed as marketing the use of any Amarin products or product candidates. Copyright to certain documents referenced below are held by their publishers. Where possible, a link is provided for access to further information about the respective publication. Note that AMR101 is the clinical name for VASCEPA® (icosapent ethyl) capsules. For more information about VASCEPA® (icosapent ethyl) capsules visit www.vascepa.com. PUBLICATIONS Cardiovascular Outcomes Trials VASCEPA® Clinical Reprints Scientific Presentations at Society Meetings VASCEPA’s Mechanisms of Action Amarin Supported Peer Reviewed Articles EPA Research, Case Studies, Overviews COVID-19 Related Publications Other Publications Referenced in Amarin’s Investor Communications For categorization of papers that support correlation between TG levels and CV risk, click here. This page was last updated on September 9, 2020. Shareholder Tools PRINTED MATERIALS EMAIL ALERTS RSS SEARCH © 2021 Amarin Corporation All rights reserved. Disclaimer Privacy Policy Contact Us Amarin is headquartered in Dublin, Ireland. In the U.S., the company's office is in Bridgewater, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN"). AMARIN, VASCEPA, VAZKEPA and REDUCE-IT are trademarks of Amarin Pharmaceuticals Ireland Limited. VAZKEPA is a registered trademark in Europe and other countries and regions and is pending registration in the United States.